News Release: July 21, 2025
News-Based Press Release: Global Polyglycolic Acid (PGA) Suture Price, Production, Latest News and Developments in 2025
For more details on Polyglycolic Acid (PGA) Suture price trend and production News, refer to the comprehensive analysis here:
Polyglycolic Acid (PGA) Suture price trend and production News
Polyglycolic Acid (PGA) Suture Price Trend in Past Five Years and Factors Impacting Price Movements (2019–2024)
Over the last five years, the Polyglycolic Acid (PGA) Suture price trend has shown dynamic fluctuations driven by a variety of industrial, economic, and geopolitical factors. From 2019 to 2021, the global average price of Polyglycolic Acid (PGA) Sutures hovered between $14,000/MT and $15,500/MT. A relative balance between supply and demand, stable raw material costs, and a consistent demand from surgical procedures kept the price stable during this period.
However, the onset of the COVID-19 pandemic in 2020 brought temporary disruptions in the supply chain, causing minor spikes in pricing. By Q2 2020, the Polyglycolic Acid (PGA) Suture price reached approximately $16,000/MT due to delayed shipments and production halts in Asia. While hospitals around the globe prioritized COVID-19 treatment, elective surgeries were deferred, reducing consumption and slightly correcting prices in the following quarters.
In 2021, as the global healthcare industry rebounded, there was a sharp surge in Polyglycolic Acid (PGA) Suture sales volume. Increased surgical activity, particularly orthopedic and gastrointestinal surgeries, raised global demand. By the end of 2021, prices touched $16,700/MT, and global manufacturers responded by expanding Polyglycolic Acid (PGA) Suture production capacities.
From 2022 to 2023, a blend of raw material cost volatility, logistics constraints, and energy price surges pushed prices upward. Q2 2022 saw prices peaking at around $17,900/MT. The spike was largely attributed to rising petroleum-based intermediate costs used in PGA synthesis and higher shipping rates. However, 2023 also marked the start of a correction phase, as production capacities expanded in regions like China and India. Competitive pricing brought the average Polyglycolic Acid (PGA) Suture price down to about $16,300/MT by the end of 2023.
In 2024, the trend continued with moderate fluctuations. Prices averaged around $15,800/MT for the year. Technological advancements in suture manufacturing and growing use of biodegradable polymers have helped in stabilizing pricing. Additionally, improved sourcing from Asian countries led to cost efficiency in production.
Environmental regulations, changing hospital procurement strategies, and raw material substitution are expected to impact pricing through 2025. With more focus on sustainable and high-performance sutures, the market is witnessing shifts in design and formulation, influencing both cost and scalability.
Estimated Quarterly Polyglycolic Acid (PGA) Suture Price Trend in 2025 ($/MT)
Q1 2025: $15,900/MT
Q2 2025: $16,050/MT
Q3 2025 (forecast): $16,300/MT
Q4 2025 (forecast): $16,200/MT
The first half of 2025 showed moderate price appreciation driven by sustained surgical demand post-pandemic and controlled input costs. While Q3 is expected to record a marginal increase due to higher procurement from hospitals and clinics globally, Q4 might witness stabilization due to seasonal demand decline and inventory normalization in key markets.
Global Polyglycolic Acid (PGA) Suture Import-Export Business Overview
The international trade of Polyglycolic Acid (PGA) Sutures has undergone a significant transformation in recent years, shaped by production diversification, increasing demand from developing economies, and trade policy changes. The export-driven model of major Asian countries, particularly China and India, continues to dominate the global supply chain, accounting for more than 60% of global exports in 2024.
China, with its vast network of medical-grade polymer manufacturers, remains the largest exporter. In 2024, the country recorded a Polyglycolic Acid (PGA) Suture sales volume exceeding 45,000 metric tons, with bulk exports directed towards the United States, Germany, Brazil, and Japan. Chinese producers have gained global preference due to cost-effective manufacturing and high-grade certifications.
India follows closely with a growing export footprint. Recent investments in domestic manufacturing capacity and R&D in bio-absorbable sutures have allowed Indian suppliers to enter premium markets such as the UK and Canada. The country exported approximately 22,000 metric tons of Polyglycolic Acid (PGA) Sutures in 2024, showing a 12% YoY growth.
On the import side, the United States continues to be the largest buyer. Due to its large and aging population and high volume of surgical procedures, the country imports about 35% of its total requirement. European nations, led by Germany and France, are also major importers, primarily sourcing from Asia to meet hospital procurement quotas.
However, emerging economies are witnessing a shift as they develop indigenous production capabilities. Countries like Brazil, South Korea, and Vietnam are taking gradual steps toward local Polyglycolic Acid (PGA) Suture production, aimed at reducing dependency and optimizing healthcare costs.
In 2024, global Polyglycolic Acid (PGA) Suture import-export trade was valued at over $2.1 billion. Export values surged as prices improved, while higher freight costs drove up landed prices in several nations. Exporters focused on regulatory compliance with ISO and USFDA standards to penetrate new regions.
In terms of trade policy, tariff relaxations under regional trade agreements helped reduce costs in APAC and Europe. The EU’s Medical Devices Regulation (MDR) has influenced sourcing patterns, as only certified suppliers are permitted under the regulation. Likewise, in North America, regulatory emphasis remains on bio-compatibility and post-surgical degradation rates.
Notably, Japan has emerged as a quality-focused importer. Japanese hospitals now demand ultra-pure sutures, driving demand for specially processed variants of PGA. While volumes remain moderate, unit prices are among the highest globally, exceeding $18,000/MT.
The trade balance remains favorable for producers in Asia, with positive net exports. However, geopolitical uncertainties and global shipping disruptions, such as those affecting the Red Sea routes in early 2025, pose risks to smooth flow of goods. Industry leaders are exploring alternate shipping corridors and partnerships with local distributors to ensure supply reliability.
Polyglycolic Acid (PGA) Suture production is projected to grow steadily, driven by robust demand in both mature and emerging surgical markets. New manufacturing plants in Malaysia and Vietnam are set to commence production by late 2025, enhancing regional availability.
With rising health awareness and increasing surgical interventions, the Polyglycolic Acid (PGA) Suture sales volume is expected to grow at 7% CAGR through 2030. Exporters are also emphasizing branding and technical documentation to gain preference in tenders and hospital procurement contracts.
The year 2025 is set to be pivotal, with continued expansion in production, new product launches featuring improved tensile strength and degradation profile, and evolving regulations pushing the market towards innovation and compliance.
For detailed market statistics, forecast, and import-export data on Polyglycolic Acid (PGA) Suture, request a sample from:
https://datavagyanik.com/reports/polyglycolic-acid-pga-suture-market-size-production-sales-average-product-price-market-share-import-vs-export/
Polyglycolic Acid (PGA) Suture Production Trends by Geography (2025)
In 2025, global Polyglycolic Acid (PGA) Suture production is witnessing a dynamic shift as countries focus on local manufacturing, cost optimization, and meeting rising demand in surgical applications. Several geographies have emerged as key players in PGA suture production, driven by technology integration, healthcare investments, and growing patient volumes.
1. Asia-Pacific (China, India, South Korea, Japan, Vietnam)
Asia-Pacific remains the global manufacturing hub for Polyglycolic Acid (PGA) Sutures, contributing to over 60% of global production in 2025. China leads the region due to its vertically integrated supply chain and abundant polymer raw materials. Chinese manufacturers are focusing on export-oriented production, with competitive pricing and high throughput. Production facilities in provinces like Zhejiang and Jiangsu have scaled significantly, with output reaching over 50,000 MT in 2024 and projected to cross 55,000 MT in 2025.
India, meanwhile, is rapidly growing its domestic production base. The Indian medical device sector, supported by government schemes, has enabled Indian companies to install state-of-the-art automated suturing lines. These units, mostly concentrated in Maharashtra and Gujarat, focus on producing both uncoated and coated variants of Polyglycolic Acid (PGA) Sutures for domestic use and export to Europe and Africa.
South Korea and Japan are smaller in terms of volume but are known for producing high-purity, specialized PGA sutures with precise degradation timelines. Japan in particular emphasizes medical-grade precision and often caters to niche applications requiring ultra-fine sutures.
Vietnam has recently entered the production space, targeting ASEAN markets. New plants in Hanoi and Ho Chi Minh City are producing basic absorbable sutures to meet growing regional demand.
2. North America (United States, Mexico)
The United States is one of the leading consumers of PGA sutures and has a developed domestic manufacturing base. Major production is concentrated in states like California, Texas, and Massachusetts, where biotech and medical device clusters exist. However, production is still limited compared to Asia due to higher costs. Nevertheless, American manufacturers focus on innovation, producing advanced biodegradable sutures with better handling and knot security.
Mexico is emerging as a low-cost production base serving both local demand and exports to South America and the US. Maquiladora zones in northern Mexico are increasingly hosting contract manufacturing units of global brands.
3. Europe (Germany, France, UK, Poland)
Germany remains the heart of Europe’s medical device production, and its PGA suture manufacturing is based on precision and strict regulatory compliance. German manufacturers produce premium-grade sutures with highly consistent absorbability. French and British companies also operate large-scale facilities that produce both standard and specialty sutures for ophthalmic and cardiovascular applications.
Eastern European countries such as Poland are now investing in PGA suture production to reduce import reliance and provide low-cost alternatives for Central European markets.
4. Latin America (Brazil, Argentina)
Brazil is leading PGA suture production in Latin America, driven by a growing domestic healthcare sector and investments in surgical consumables. Production facilities in São Paulo and Rio de Janeiro are capable of meeting regional demand, with excess capacity aimed at exports to Africa and Southeast Asia.
Argentina has smaller-scale manufacturing operations that focus on supplying local hospitals and private clinics.
5. Middle East & Africa
In the Middle East, countries like the UAE and Saudi Arabia are investing in small-scale production units as part of healthcare localization initiatives. These facilities are still dependent on imported raw materials and machinery but are expected to grow steadily.
Africa continues to be largely dependent on imports, though some pilot manufacturing initiatives are underway in South Africa and Kenya with support from multinational organizations.